Skip Navigation


Journal of Tropical Pediatrics Advance Access originally published online on July 10, 2007
Journal of Tropical Pediatrics 2007 53(5):325-330; doi:10.1093/tropej/fmm038
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
53/5/325    most recent
fmm038v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in J Trop Pediatr
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kumar, V.
Right arrow Articles by Kabra, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, V.
Right arrow Articles by Kabra, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial

Vikram Kumara, P. Ramesha, Rakesh Lodhaa, R. M. Pandeyb and S. K. Kabraa

Departments of aPediatrics andbDepartment of Biostatistics, AIIMS, Ansari Nagar, New Delhi 110029

Correspondence: Dr S. K. Kabra, Additional Professor, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029. E-mail: < skkabra{at}hotmail.com>.


  Abstract

Background: Guidelines recommend daily controller therapy for mild persistent asthma. Montelukast has demonstrated consistent benefit in controlling symptoms of asthma and may be an alternative, orally administered, nonsteroidal agent for treating mild asthma.

Aim: To determine whether montelukast is as effective as budesonide in controlling mild persistent asthma as determined by FEV1.

Methods: Between November 2003 to October 2005, participants aged 5–15 years with recently diagnosed mild persistent asthma (n = 62) were randomized to oral montelukast (5 mg daily) [N1 = 30] or inhaled budesonide (400 µg per day in two doses) [N2 = 32] in a single center, double-blind study.

Results: Baseline demographic and spirometric parameters were comparable. The median (95% confidence interval) percentage predicted FEV1 was similar in the two groups after 12 weeks of treatment (budesonide: 76.70 (67.96–90.53%), montelukast: 75 (67.40–88.47)%; p = 0.44). There was similar improvement in spirometric parameters and clinical symptom scores in both the groups. There was no statistically significant difference between the groups in the need for rescue drugs as well as side effects reported by parents.

Conclusion: Montelukast is as effective as inhaled budesonide in the treatment of mild persistent asthma in children aged 5–15 years. Montelukast may be used as an alternative to low dose inhaled corticosteroids for management of mild persistent asthma.

Key Words: mild persistent asthma • montelukast • budesonide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in J Trop Pediatr:

In this Issue October 2007

J Trop Pediatr 2007 53: i. [Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.